Table 1 Demographic and baseline clinical characteristics of participants in the trial of switching to aripiprazole by the grouping of prolactin levels at follow up
Characteristic | Total (N = 63) | Normal prolactin level at follow up (N = 38) | Abnormally low prolactin level at follow up (N = 25) | Pa |
|---|---|---|---|---|
Male, n (%) | 26 (41.27) | 10 (26.32) | 16 (64.00) | 0.003** |
Age, years, (SD) | 38.7 (11.29) | 37.7 (12.25) | 40.2 (9.69) | 0.38 |
Body height, cm, mean (SD) | 162.3 (8.83) | 159.5 (7.77) | 166.6 (8.78) | 0.003** |
Body weight, kg, mean (SD) | 66.6 (11.96) | 63.5 (12.53) | 71.4 (9.36) | 0.008** |
Age of onset, years, mean (SD)b | 27.7 (8.81) | 28.8 (9.73) | 26.1 (7.14) | 0.44 |
Early age of onset, n (%) b | 8 (12.70) | 6 (15.79) | 2 (8.00) | 0.46 |
Late dropout, n (%) | 10 (15.87) | 7 (18.42) | 3 (12.00) | 0.23 |
Prolactin level, ng/dL, mean (SD) | ||||
 Baseline | 53.9 (61.38) | 74.0 (69.94) | 20.8 (20.35) | 0.001** |
 14th Day | 23.5 (35.15) | 31.7 (38.81) | 11.0 (24.51) | < 0.001** |
 56th Dayc | 6.9 (6.03) | 10.0 (6.05) | 2.4 (1.18) | < 0.001** |
Positive subscore in PANSS at baseline, mean (SD)d | 10.3 (4.48) | 10.7 (4.54) | 9.8 (4.43) | 0.45 |
Switching strategy in previous trial, n (%) | Â | Â | Â | 0.88 |
 Fast strategy | 32 (50.79) | 19 (50.00) | 13 (52.00) |  |
 Slow strategy | 31 (49.21) | 19 (50.00) | 12 (48.00) |  |
Preswitching antipsychoticse | Â | Â | Â | 0.32 |
 High risk of prolactin elevation (RIS or AMI), n (%) | 16 (25.39) | 12 (31.00) | 4 (16.00) |  |
 Medium risk of prolactin elevation (FGA or ZOT), n (%) | 18 (28.57) | 9 (24.00) | 9 (36.00) |  |
 Low risk (OLA or ZIP or QUE), n (%) | 29 (46.03) | 17 (45.00) | 12 (48.00) |  |
 Chlorpromazine equivalent dose, mean (SD) | 289.0 (231.80) | 289.1 (260.80) | 288.9 (184.30) | 0.71 |